Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: From structural findings to molecules

npj Schizophrenia

Volumn 1, Issue , 2015, Pages

  Cassoli, Juliana Silva ^a   Guest, Paul C ^a   Malchow, Berend ^b   Schmitt, Andrea ^b,c   Falkai, Peter ^b   Martins De Souza, Daniel ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 CYCLIC NUCLEOTIDE 3 PHOSPHODIESTERASE; CLAUDIN 11; ERBB PROTEIN; ERMIN PROTEIN; GELSOLIN; HYALURONAN AND PROTEOGLYCAN LINK HYALUPROTEIN 2; MEMBRANE PROTEIN; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NRG1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PROTEOLIPID PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG;

CELL DAMAGE; DISEASE SEVERITY; DRUG TARGETING; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; HUMAN; MENTAL DISEASE; MYELINATION; NERVE CONDUCTION; NERVE FIBER; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WHITE MATTER;

EID: 84969299550     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/npjschz.2015.34     Document Type: Review

References (159)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250: 274-285.
2. Häfner H, an der Heiden W. Schizophrenia. Blackwell Science: 2007; 101-141.
3. WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision 4th edn. WHO Library: Geneva, Switzerland, 2010.
4. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci 2010; 12: 393-407.
5. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-378.
6. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421-427.
7. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. Front Neurosci 2014; 8: 19.
8. Girard TA, Christensen BK, Rizvi S. Visual-spatial episodic memory in schizophrenia: A multiple systems framework. Neuropsychology 2010; 24: 368-378.
9. Falkai P, Schmitt A, Cannon TD. Pathophysiology of schizophrenia In: Gaebel W (ed). Schizophrenia: Current Science and Clinical Practice. Wiley-Blackwell: Oxford, UK, 2011; 31-65.
10. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012; 27: 432-436.
11. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 1995; 3: 89-97.
12. Andreasen NC. A unitary model of schizophrenia: Bleuler's ?fragmented phrene? as schizencephaly. Arch Gen Psychiatry 1999; 56: 781-787.
13. Crow TJ, Paez P, Chance SA. Callosal misconnectivity and the sex difference in psychosis. Int Rev Psychiatry 2007; 19: 449-457.
14. Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009; 108: 3-10.
15. Yao L, Lui S, Liao Y, Du MY, Hu N, Thomas JA et al. White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 100-106.
16. Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 2003; 8: 811-820.
17. Hoistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat 2009; 3: 9.
18. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361-370.
19. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075-1085.
20. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269-275.
21. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94: 273-280.
22. Schmitt A, Steyskal C, Bernstein HG, Schneider-Axmann T, Parlapani E, Schaeffer EL et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 2009; 117: 395-407.
23. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 2006; 85: 245-253.
24. Vostrikov V, Orlovskaya D, Uranova N. Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J Biol Psychiatry 2008; 9: 34-42.
25. Segal D, Schmitz C, Hof PR. Spatial distribution and density of oligodendrocytes in the cingulum bundle are unaltered in schizophrenia. Acta Neuropathol 2009; 117: 385-394.
26. Williams MR, Hampton T, Pearce RK, Hirsch SR, Ansorge O, Thom M et al. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013; 263: 41-52.
27. Williams RW, Rakic P. Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J Comp Neurol 1988; 278: 344-352.
28. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203-212.
29. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of populationbased studies. Psychol Med 2013; 43: 239-257.
30. Nicodemus KK, Marenco S, Batten AJ, Vakkalanka R, Egan MF, Straub RE et al. Serious obstetric complications interact with hypoxia-regulated/vascularexpression genes to influence schizophrenia risk. Mol Psychiatry 2008; 13: 873-877.
31. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012; 71: 444-457.
32. Chew LJ, Fusar-Poli P, Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev Neurosci 2013; 35: 102-129.
33. Fendt M, Lex A, Falkai P, Henn FA, Schmitt A. Behavioural alterations in rats following neonatal hypoxia and effects of clozapine: implications for schizophrenia. Pharmacopsychiatry 2008; 41: 138-145.
34. Sommer JU, Schmitt A, Heck M, Schaeffer EL, Fendt M, Zink M et al. Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260(Suppl 2): S81-S89.
35. Schmidt-Kastner R, van Os J, Esquivel G, Steinbusch HWM, Rutten BPF. An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. Mol Psychiatry 2012; 17: 1194-1205.
36. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK et al. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 2001; 220: 175-186.
37. Maltepe E, Simon MC. Oxygen, genes, and development: an analysis of the role of hypoxic gene regulation during murine vascular development. J Mol Med (Berl) 1998; 76: 391-401.
38. Kaur C, Sivakumar V, Ang LS, Sundaresan A. Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicity. J Neurochem 2006; 98: 1200-1216.
39. Hanisch UK. Microglia as a source and target of cytokines. Glia 2002; 40: 140-155.
40. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 115-121.
41. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011; 91: 461-553.
42. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2005; 43: 81-89.
43. Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease courserelated immune alterations? Brain Behav Immun 2012; 26: 1273-1279.
44. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006; 112: 305-316.
45. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
46. Schnieder TP, Dwork AJ. Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 2011; 69: 134-139.
47. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807.
48. Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 2007; 92: 108-115.
49. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010; 64: 217-230.
50. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015; 161: 102-112.
51. Schmitz T, Krabbe G, Weikert G, Scheuer T, Matheus F, Wang Y et al. Minocycline protects the immature white matter against hyperoxia. Exp Neurol 2014; 254: 153-165.
52. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
53. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 2004; 77: 858-866.
54. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-69743.
55. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
56. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- and astrocyteassociated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 2009; 112: 54-64.
57. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 2008; 33: 2993-3009.
58. Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P et al. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res 2010; 120: 150-158.
59. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry 2009; 14: 1083-1094.
60. Wu JQ, Wang X, Beveridge NJ, Tooney PA, Scott RJ, Carr VJ et al. Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia. PLoS One 2012; 7: e36351.
61. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyterelated gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 2005; 79: 157-173.
62. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelinassociated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 2006; 21: 531-540.
63. Weidenhofer J, Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone. Mol Cell Neurosci 2006; 31: 243-250.
64. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 2007; 90: 15-27.
65. Bronstein JM, Tiwari-Woodruff S, Buznikov AG, Stevens DB. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease. J Neurosci Res 2000; 59: 706-711.
66. Gow A, Southwood CM, Li JS, Pariali M, Riordan GP, Brodie SE et al. CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 1999; 99: 649-659.
67. Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci USA 2006; 103: 7482-7487.
68. Chambers JS, Perrone-Bizzozero NI. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem Res 2004; 29: 2293-2302.
69. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin MN et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 2009; 43: 978-986.
70. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009; 259: 151-163.
71. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009; 116: 275-289.
72. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9: 3368-3382.
73. Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry 2011; 16: 1189-1202.
74. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 2010; 44: 1176-1189.
75. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-721.
76. Drummond GI, Iyer NT, Keith J. Hydrolysis of Ribonucleoside 2',3'-Cyclic Phosphates by a Diesterase from Brain. J Biol Chem 1962; 237: 3535-3539.
77. Mazumder R, Iyer LM, Vasudevan S, Aravind L. Detection of novel members, structure-function analysis and evolutionary classification of the 2H phosphoesterase superfamily. Nucleic Acids Res 2002; 30: 5229-5243.
78. Trapp BD, Bernier L, Andrews SB, Colman DR. Cellular and subcellular distribution of 2',3'-cyclic nucleotide 3'-phosphodiesterase and its mRNA in the rat central nervous system. J Neurochem 1988; 51: 859-868.
79. Agrawal HC, Sprinkle TJ, Agrawal D. 2',3'-cyclic nucleotide-3'-phosphodiesterase in the central nervous system is fatty-acylated by thioester linkage. J Biol Chem 1990; 265: 11849-11853.
80. Braun PE, De Angelis D, Shtybel WW, Bernier L. Isoprenoid modification permits 2',3'-cyclic nucleotide 3'-phosphodiesterase to bind to membranes. J Neurosci Res 1991; 30: 540-544.
81. Bifulco M, Laezza C, Stingo S, Wolff J. 2',3'-Cyclic nucleotide 3'-phosphodiesterase: a membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc Natl Acad Sci USA 2002; 99: 1807-1812.
82. Lee J, Gravel M, Zhang R, Thibault P, Braun PE. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J Cell Biol 2005; 170: 661-673.
83. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A et al. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 2006; 63: 18-24.
84. Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci USA 2006; 103: 12469-12474.
85. Edgar NM, Touma C, Palme R, Sibille E. Resilient emotionality and molecular compensation in mice lacking the oligodendrocyte-specific gene Cnp1. Transl Psychiatry 2011; 1: e42.
86. Harauz G, Ladizhansky V, Boggs JM. Structural polymorphism and multifunctionality of myelin basic protein. Biochemistry 2009; 48: 8094-8104.
87. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001; 81: 871-927.
88. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci 2004; 1025: 84-91.
89. Parlapani E, Schmitt A, Erdmann A, Bernstein HG, Breunig B, Gruber O et al. Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Res 2009; 1301: 126-134.
90. Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 2005; 7: 449-455.
91. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-1730.
92. Jahn O, Tenzer S, Werner HB. Myelin proteomics: molecular anatomy of an insulating sheath. Mol Neurobiol 2009; 40: 55-72.
93. Greer JM, Lees MB. Myelin proteolipid protein - the first 50 years. Int J Biochem Cell Biol 2002; 34: 211-215.
94. Daffu G, Sohi J, Kamholz J. Proteolipid protein dimerization at cysteine 108: Implications for protein structure. Neurosci Res 2012; 74: 144-155.
95. Dhaunchak AS, Nave KA. A common mechanism of PLP/DM20 misfolding causes cysteine-mediated endoplasmic reticulum retention in oligodendrocytes and Pelizaeus-Merzbacher disease. Proc Natl Acad Sci USA 2007; 104: 17813-17818.
96. Tanaka H, Ma J, Tanaka KF, Takao K, Komada M, Tanda K et al. Mice with altered myelin proteolipid protein gene expression display cognitive deficits accompanied by abnormal neuron-glia interactions and decreased conduction velocities. J Neurosci 2009; 29: 8363-8371.
97. Trapp BD, Quarles RH. Presence of the myelin-associated glycoprotein correlates with alterations in the periodicity of peripheral myelin. J Cell Biol 1982; 92: 877-882.
98. Kursula P, Lehto VP, Heape AM. The small myelin-associated glycoprotein binds to tubulin and microtubules. Brain Res Mol Brain Res 2001; 87: 22-30.
99. Felsky D, Voineskos AN, Lerch JP, Nazeri A, Shaikh SA, Rajji TK et al. Myelinassociated glycoprotein gene and brain morphometry in schizophrenia. Front Psychiatry 2012; 3: 40.
100. Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci USA 2003; 100: 11059-11064.
101. Cannon DM, Walshe M, Dempster E, Collier DA, Marshall N, Bramon E et al. The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives. Transl Psychiatry 2012; 2: e167.
102. Brockschnieder D, Sabanay H, Riethmacher D, Peles E. Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology. J Neurosci 2006; 26: 757-762.
103. Vouyiouklis DA, Brophy PJ. A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J Neurochem 1997; 69: 995-1005.
104. Hirakawa S, Oohashi T, Su WD, Yoshioka H, Murakami T, Arata J et al. The brain link protein-1 (BRAL1): cDNA cloning, genomic structure, and characterization as a novel link protein expressed in adult brain. Biochem Biophys Res Commun 2000; 276: 982-989.
105. Crichton RR, Charloteaux-Wauters M. Iron transport and storage. Eur J Biochem 1987; 164: 485-506.
106. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 2006; 11: 459-470, 23.
107. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
108. Ahrendsen JT, Macklin W. Signaling mechanisms regulating myelination in the central nervous system. Neurosci Bull 2013; 29: 199-215.
109. Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P. Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 5): 35-39.
110. Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N et al. Type III neuregulin-1 is required for normal sensorimotor gating, memoryrelated behaviors, and corticostriatal circuit components. J Neurosci 2008; 28: 6872-6883.
111. Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, Harrison PJ et al. Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. Neuroreport 2009; 20: 1523-1528.
112. Agarwal A, Zhang M, Trembak-Duff I, Unterbarnscheidt T, Radyushkin K, Dibaj P et al. Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity. Cell Rep 2014; 8: 1130-1145.
113. Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260: 101-111.
114. Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE et al. Isoform-specific expression and function of neuregulin. Development 1997; 124: 3575-3586.
115. Birchmeier C. ErbB receptors and the development of the nervous system. Exp Cell Res 2009; 315: 611-618.
116. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
117. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437-452.
118. Lai C, Feng L. Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes. Biochem Biophys Res Commun 2004; 314: 535-542.
119. Bao J, Wolpowitz D, Role LW, Talmage DA. Back signaling by the Nrg-1 intracellular domain. J Cell Biol 2003; 161: 1133-1141.
120. Luo X, Prior M, He W, Hu X, Tang X, Shen W et al. Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. J Biol Chem 2011; 286: 23967-23974.
121. Watkins TA, Emery B, Mulinyawe S, Barres BA. Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 2008; 60: 555-569.
122. Colognato H, Tzvetanova ID. Glia unglued: how signals from the extracellular matrix regulate the development of myelinating glia. Dev Neurobiol 2011; 71: 924-955.
123. O'Kusky J, Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 2012; 33: 230-251.
124. Furusho M, Dupree JL, Nave KA, Bansal R. Fibroblast growth factor receptor signaling in oligodendrocytes regulates myelin sheath thickness. J Neurosci 2012; 32: 6631-6641.
125. Colognato H, Baron W, Avellana-Adalid V, Relvas JB, Baron-Van Evercooren A, Georges-Labouesse E et al. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat Cell Biol. 2002; 4: 833-841.
126. Chun SJ, Rasband MN, Sidman RL, Habib AA, Vartanian T. Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J Cell Biol 2003; 163: 397-408.
127. Ye P, Umayahara Y, Ritter D, Bunting T, Auman H, Rotwein P et al. Regulation of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice expressing an IGF-I-luciferase fusion gene. Endocrinology 1997; 138: 5466-5475.
128. Carson MJ, Behringer RR, Brinster RL, McMorris FA. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993; 10: 729-740.
129. Ye P, Carson J, D'Ercole AJ. In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J Neurosci 1995; 15: 7344-7356.
130. Goddard DR, Berry M, Butt AM. In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system. J Neurosci Res 1999; 57: 74-85.
131. Ye P, Li L, Richards RG, DiAugustine RP, D'Ercole AJ. Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 2002; 22: 6041-6051.
132. Zeger M, Popken G, Zhang J, Xuan S, Lu QR, Schwab MH et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007; 55: 400-411.
133. Riva MA, Mocchetti I. Developmental expression of the basic fibroblast growth factor gene in rat brain. Brain Res Dev Brain Res 1991; 62: 45-50.
134. Matsuyama A, Iwata H, Okumura N, Yoshida S, Imaizumi K, Lee Y et al. Localization of basic fibroblast growth factor-like immunoreactivity in the rat brain. Brain Res 1992; 587: 49-65.
135. Ratzka A, Baron O, Grothe C. FGF-2 deficiency does not influence FGF ligand and receptor expression during development of the nigrostriatal system. PLoS One 2011; 6: e23564.
136. Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470-7479.
137. Furusho M, Kaga Y, Ishii A, Hebert JM, Bansal R. Fibroblast growth factor signaling is required for the generation of oligodendrocyte progenitors from the embryonic forebrain. J Neurosci 2011; 31: 5055-5066.
138. Baron W, de Jonge JC, de Vries H, Hoekstra D. Perturbation of myelination by activation of distinct signaling pathways: an in vitro study in a myelinating culture derived from fetal rat brain. J Neurosci Res 2000; 59: 74-85.
139. Wang Z, Colognato H, Ffrench-Constant C. Contrasting effects of mitogenic growth factors on myelination in neuron-oligodendrocyte co-cultures. Glia 2007; 55: 537-545.
140. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005; 47: 681-694.
141. Barros CS, Nguyen T, Spencer KS, Nishiyama A, Colognato H, Muller U. Beta1 integrins are required for normal CNS myelination and promote AKT-dependent myelin outgrowth. Development 2009; 136: 2717-2724.
142. Ness JK, Mitchell NE, Wood TL. IGF-I and NT-3 signaling pathways in developing oligodendrocytes: differential regulation and activation of receptors and the downstream effector Akt. Dev Neurosci 2002; 24: 437-445.
143. Flores AI, Narayanan SP, Morse EN, Shick HE, Yin X, Kidd G et al. Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci 2008; 28: 7174-7183.
144. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 2009; 29: 6367-6378.
145. Wesseling H, Rahmoune H, Tricklebank M, Guest PC, Bahn S. A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. J Proteome Res 2015; 14: 411-421.
146. Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 2013; 73: 1189-1198.
147. Gururajan A, van den Buuse M. Is the mTOR-signalling cascade disrupted in Schizophrenia? J Neurochem 2014; 129: 377-387.
148. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1774-1779.
149. Gerace E, Moazed D. Affinity Purification of Protein Complexes Using TAP Tags. Methods Enzymol 2015; 559: 37-52.
150. Thomas S, Bonchev D. A survey of current software for network analysis in molecular biology. Hum Genomics 2010; 4: 353-360.
151. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010; 38: W214-W220.
152. Seiwa C, Yamamoto M, Tanaka K, Fukutake M, Ueki T, Takeda S et al. Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination. J Neurosci Res 2007; 85: 954-966.
153. Seki Y, Kato TA, Monji A, Mizoguchi Y, Horikawa H, Sato-Kasai M et al. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-gamma-stimulated microglia in coculture model. Schizophr Res 2013; 151: 20-28.
154. Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM et al. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol 2015; 35: 374-381.
155. Leza JC, Garcia-Bueno B, Bioque M, Arango C, Parellada M, Do K et al. Inflammation in schizophrenia: A question of balance. Neurosci Biobehav Rev 2015; 55: 612-626.
156. Mitew S, Hay CM, Peckham H, Xiao J, Koenning M, Emery B. Mechanisms regulating the development of oligodendrocytes and central nervous system myelin. Neuroscience 2014; 276: 29-47.
157. Bou Khalil R. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses. 2011; 77: 427-429.
158. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res 2015; 161: 4-18.
159. Taveggia C, Feltri ML, Wrabetz L. Signals to promote myelin formation and repair. Nat Rev Neurol 2010; 6: 276-287.